The Task Force members have recently observed an unusual imaging pattern on FDG PET/CT or FDG PET/MR that may be due to COVID-19 infection. 

Image courtesy of SNMMI


January 17, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) issued a statement on Jan. 14 regarding the possible effect of Omicron infection on FDG PET/CT scans. As a professional society representing more than 16,000 nuclear medicine professionals, it is SNMMI’s responsibility to distribute information relevant to the evolving COVID-19 pandemic to its members as we navigate through various ups and downs of each successive wave. Over the past 18 months, the SNMMI COVID-19 Task Force has met bi-weekly to monitor, support, educate, and provide guidance to the nuclear medicine and molecular imaging community. 

The Task Force members have recently observed an unusual imaging pattern on FDG PET/CT or FDG PET/MR that may be due to COVID-19 infection. 

Unlike the FDG PET/CT pattern seen with infections from previous strains of COVID-19, with principal involvement of the lungs, this new array of findings is primarily centered in the upper aerodigestive tract and cervical lymph nodes. Specifically, there is prominent, symmetric FDG uptake throughout the nasopharynx, oropharynx and tonsils with or without associated FDG-avid cervical lymphadenopathy, particularly in the suprahyoid neck. Based on what we know about the Omicron variant, it is conceivable that this pattern, whenever correlated with COVID-19 infection, is a result of the presently dominant Omicron strain. 

The Task Force recommends that this pattern should be taken into consideration at the time of FDG PET/CT interpretations and the possibility of infection with Omicron variant of COVID-19 should be entertained in the differential diagnosis. Since this pattern can by no means be diagnostic of COVID-19 infection, the Task Force makes the following recommendations.

  1. Check the patient records to see if there is a recent positive COVID-19 test.
  2. Determine if the patient is at higher risk of COVID-19 infection based on current symptoms or due to recent exposure or travel. If so, a recommendation can be made to test for COVID-19 in the appropriate setting.
  3. Compare with prior FDG PET/CT examinations and the patient’s history to determine if this represents chronic inflammatory/reactive process or stable malignancy such as lymphoma.
  4. Various differential diagnostic possibilities should be considered if this pattern is new or if there is interval progression including, but not limited to, infection with COVID-19, other viruses such as Epstein-Barr virus, malignancy and bacterial infections.
  5. This pattern may also be seen in children and younger adults but should be interpreted cautiously in view of normal increased activity that can be physiologic. Correlation with history and symptoms and comparison to prior examinations is recommended.

For more information: www.snmmi.org

Related Radiology COVID-19 Content:

Medical AI Models Rely on 'Shortcuts' That Could Lead to Misdiagnosis of COVID-19

CT Provides Best Diagnosis for Novel Coronavirus (COVID-19)

SNMMI Image of the Year: PET Imaging Measures Cognitive Impairment in COVID-19 Patients

Cardiac MRI Effective in Detecting Asymptomatic, Symptomatic Myocarditis in Athletes

PHOTO GALLERY: How COVID-19 Appears on Medical Imaging

VIDEO: How to Image COVID-19 and Radiological Presentations of the Virus — Interview with Margarita Revzin, M.D.

How Does COVID-19 Appear in the Lungs?

Find more radiology related COVID news and video

PHOTO GALLERY: How COVID-19 Appears on Medical Imaging


Related Content

News | PET Imaging

February 9, 2024 — A novel PET imaging technique can noninvasively detect active inflammation in the body before ...

Time February 09, 2024
arrow
News | SNMMI

February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...

Time February 06, 2024
arrow
News | FDA

January 23, 2024 — Siemens Healthineers announces the Food and Drug Administration (FDA) clearance of syngo Virtual ...

Time January 23, 2024
arrow
News | Artificial Intelligence

January 23, 2024 — Quibim announced it has added an industry-leading cancer detection capability to its prostate tool ...

Time January 22, 2024
arrow
Feature | PET-CT | By Melinda Taschetta-Millane

According to research conducted by Polaris Market Research, the global positron emission tomography (PET)/computed ...

Time January 17, 2024
arrow
News | PET Imaging

January 16, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of Nuclear ...

Time January 16, 2024
arrow
News | Prostate Cancer

January 5, 2024 — Perspective Therapeutics, Inc., announced that it has entered into a patent license agreement with ...

Time January 05, 2024
arrow
News | Radiology Business

December 27, 2023 — The American Roentgen Ray Society (ARRS) announced David M. Naeger, MD, as the 2024 ARRS ...

Time December 27, 2023
arrow
News | Radiopharmaceuticals and Tracers

December 6, 2023 — Philochem AG, a wholly owned subsidiary of Philogen S.p.A., and Blue Earth Diagnostics, a Bracco ...

Time December 06, 2023
arrow
News | RSNA

December 1, 2023 — In today's healthcare environment, the industry faces various pressing challenges. The magnetic ...

Time December 01, 2023
arrow
Subscribe Now